| Breast Cancer |
1 |
1 |
| Triple Negative Breast Cancer |
0 |
1 |
| Biologic Therapy |
0 |
0.7 |
| Breast |
0 |
0.58 |
| Cancer |
0 |
0.58 |
| Ovarian Cancer |
0 |
0.56 |
| Targeted Cancer Therapy |
0 |
0.47 |
| Genomic Medicine |
0 |
0.44 |
| Chemotherapy |
0 |
0.27 |
| Neoadjuvant Therapy |
0 |
0.27 |
| Adjuvant Chemotherapy |
0 |
0.21 |
| Tumor |
0 |
0.21 |
| Vaccines |
0 |
0.14 |
| Receptors |
0 |
0.12 |
| Surgery |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Clinical Research |
0 |
0.09 |
| Immunotherapy |
0 |
0.09 |
| Adjuvant Setting |
0 |
0.06 |
| Axillary Region |
0 |
0.06 |
| BRCA |
0 |
0.06 |
| Fellowship |
0 |
0.06 |
| Lymph Node |
0 |
0.06 |
| Preoperative |
0 |
0.06 |
| Residual Disease |
0 |
0.06 |
| Estrogen |
0 |
0.05 |
| Adjuvant Therapy |
0 |
0.03 |
| Anthracyclines |
0 |
0.03 |
| Biomarker |
0 |
0.03 |
| Biopsy |
0 |
0.03 |
| Dorsum |
0 |
0.03 |
| Endocrine Therapy |
0 |
0.03 |
| Fertility |
0 |
0.03 |
| Food and Drug Administration (FDA) |
0 |
0.03 |
| Genetics |
0 |
0.03 |
| Ohio |
0 |
0.03 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.03 |
| Professional Development |
0 |
0.03 |
| Residency |
0 |
0.03 |
| Taxane |
0 |
0.03 |